How to Prove Trial Feasibility and Win Site Selection

Featured Image: An operational command-center visualization showing real-time site execution workflows, trial milestone analytics, and patient pipeline integrity. Designed in a deep navy base accented with vibrant operational-excellence green data telemetry.

As a Lead Clinical Research Coordinator, you are intimately familiar with the Friday afternoon crisis: a 45-page Feasibility Questionnaire (FQR) hits your inbox with a 72-hour turnaround deadline.

The sponsor wants to know your exact prevalence of treatment-naïve patients matching eight strict inclusion criteria and twelve hyper-specific exclusion parameters. You already have three monitor visits scheduled, four patient infusions to oversee, and two protocol amendments to route through the IRB.

So what happens? Like most overburdened coordinators, you pull a broad diagnostic billing code query from your electronic health record (EHR), apply a rough percentage filter based on gut instinct, and submit the response.

You are not alone in this compromise, but the industry data reveals a painful reality: nearly 86% of clinical trials fail to meet their original enrollment timelines , and industry analyses reveal that 11% of selected trial sites never enroll a single participant .

Sponsors and Clinical Research Organizations (CROs) have grown deeply cynical of optimistic feasibility estimates. When reviewing site selection proposals, study feasibility teams routinely discount coordinator estimates by 30% to 50% simply because self-reported operational capabilities rarely match real-world trial execution.

To secure premier, high-impact clinical trials, lead coordinators must transition from optimistic estimations to verifiable operational capability. Sponsors do not award trials to sites with the biggest patient promises; they award them to sites that can demonstrably prove their execution infrastructure.

Here is how you can transform your feasibility workflow, elevate sponsor collaboration, and establish your site as an elite execution partner using the TheraNovex TrialMatch platform.

The Operational Feasibility Dilemma: Why Traditional Estimates Fail

Every failed trial timeline leaves scars on both sides of the industry. For sponsors, an unselected or non-performing site represents hundreds of thousands of dollars in wasted start-up costs, monitoring overhead, and lost patent exclusivity days. For the lead coordinator, taking on a trial that is fundamentally misaligned with your actual clinic workflow leads to team burnout, protocol deviations, and strained sponsor relationships.

The breakdown almost always traces back to the initial site selection phase. Traditional trial feasibility relies on flawed methodologies:

1. Static EHR Code Queries: Pulling an ICD-10 or CPT code list shows who was diagnosed or treated in the past, not who meets multi-layered clinical parameters today, who is cognitively willing to participate, or who has transportation access. 2. Disconnected Staffing Capacity: Feasibility surveys ask about cold physical metrics—freezer capacity, centrifuge availability, and exam rooms—while overlooking dynamic operational capacity. They rarely capture whether your clinical coordinators actually have the cognitive bandwidth to manage complex pharmacokinetic (PK) blood draws alongside aggressive visit schedules. 3. The Communication Gap: Sponsors send standardized forms that fail to account for site-specific nuances, while sites return inflated estimates to remain competitive, creating a cycle of mutual distrust.

This is precisely where TheraNovex disrupts the cycle. The TheraNovex TrialMatch platform replaces manual diagnostic searches and inflated guesses with real-time, precision-matched cohort modeling. Instead of scrambling through unverified medical records, coordinators can demonstrate verified protocol fit before signing a contract.

4 Actionable Strategies to Prove Execution Capability to Sponsors

To distinguish your site during competitive site selection reviews, you must deliver precision, transparency, and data integrity. Below are four actionable ways to prove your operational readiness.

1. Replace Retrospective EHR Queries with Real-Time Protocol Modeling

Sponsors evaluate dozens of sites for a single protocol footprint. If your feasibility response relies on generalities—such as "Our database contains over 1,500 patients with type 2 diabetes" —your submission will likely be dismissed.

A high-performing coordinator submits granular data: "Across our active cohort of 1,500 type 2 diabetes patients, exactly 84 meet the HbA1c threshold between 7.5% and 9.5%, have not initiated an SGLT2 inhibitor in the last 6 months, and have an eGFR above 45 mL/min/1.73m²."

Actionable Step: Build strict pre-screening criteria funnels into your feasibility review process. Rather than relying on simple code searches, screen against full inclusion/exclusion matrices. The TheraNovex Advantage: The TheraNovex TrialMatch platform automatically ingests complex protocol criteria and maps them against live, multi-source patient data streams. Instead of spending 15 hours of manual chart-checking, coordinators leverage TrialMatch to generate verified patient counts in minutes. This data-driven precision has been shown to reduce site pre-screening time by 45% , allowing you to return ironclad feasibility questionnaires days ahead of your competition.

2. Turn Diversity and Engagement Goals into Pre-Validated Metrics

Regulatory agencies like the FDA have made Diversity Action Plans a central pillar of protocol approval. Sponsors are under enormous pressure to select sites that do not merely promise demographic diversity, but have established pathways to enroll historically underrepresented groups.

When coordinators submit vague assurances like "We serve a diverse metropolitan population," they leave sponsors uncertain. Feasibility teams need verifiable demographics backed by demonstrated engagement.

Actionable Step: Pair your demographic metrics with specific, community-based operational strategies. Document historical consent rates, language accessibility workflows, and transport assistance infrastructure directly within your feasibility documentation. The TheraNovex Advantage: TheraNovex connects sites with proprietary, pre-engaged community patient networks. Through the TrialMatch interface, lead coordinators can present sponsors with an immediate, demographically verified patient pipeline. By integrating TheraNovex’s targeted patient engagement tools, sites demonstrate to sponsors that their diversity commitments are supported by active digital pipelines, improving enrollment equity and study retention.

3. Conduct Pre-Emptive Capacity and Workflow Audits

A common reason sites fail to execute is unexpected operational friction: a protocol requires a 4-hour post-dose observation window, but the site’s infusion suites are fully booked by standard-of-care patients on Tuesdays and Thursdays.

Proving operational capability means auditing your clinic’s physical constraints, coordinator labor allocation, and pharmacy logistics before finalizing your feasibility response.

Actionable Step: Maintain a living operational matrix that tracks coordinator-to-patient ratios, equipment calibration schedules, and lab turnaround windows. Share this operational transparency with the CRO during the Site Qualification Visit (SQV). Demonstrating that you understand your own operational limitations builds immense trust. The TheraNovex Advantage: TheraNovex’s site interface pairs patient demand with operational resource requirements. By evaluating the operational weight of a protocol against current trial commitments, TrialMatch prevents sites from over-promising and under-delivering. This clear assessment provides CROs with an accurate view of your actual capacity, transforming the traditional tension of site selection into a collaborative process.

4. Provide Verifiable Patient Funnels, Not Raw Numbers

Sponsors are tired of the traditional funnel paradox: a site reports 200 eligible patients, identifies 20 during pre-screening, consents 5, and randomizes 1.

Elite coordinators present a pre-validated conversion funnel in their feasibility responses: Total Identified Candidates Clinically Excluded (based on lab/medication criteria) Operationally Excluded (distance, schedule conflicts, transportation) Highly Probable Consents

Actionable Step: In your feasibility narratives, outline your historical conversion ratios for the therapeutic area. Proactively addressing drop-off points demonstrates deep operational experience. The TheraNovex Advantage: The TheraNovex TrialMatch platform models conversion likelihood based on dynamic patient eligibility scoring. By evaluating clinical history alongside active patient intent, TrialMatch provides verified funnel data. Sites utilizing TheraNovex routinely see a 92% enrollment predictability rate , virtually eliminating the drop-off issues that disrupt study budgets and timelines.

Transforming Site-Sponsor Collaboration into Long-Term Partnerships

When coordinators rely on fragmented software, static spreadsheets, and manual chart reviews, trial feasibility feels like an endless administrative burden. This approach frustrates coordinators and leaves sponsors guessing about true site potential.

True sponsor collaboration occurs when both entities operate from a single source of operational truth.

Conventional Site Feasibility: [Guesswork & Broad EHR Searches] ➔ [Inflated FQR Submission] ➔ [Sponsor Skepticism] ➔ [Delayed Study Timelines]

TheraNovex-Powered Feasibility: [Protocol-Specific Algorithmic Matching] ➔ [Validated Cohort funnels] ➔ [Data-Driven Selection] ➔ [On-Time Enrollment]

When you incorporate the TheraNovex TrialMatch platform into your site's standard operating procedure, your feasibility submissions shift from speculative bids to data-backed commitments. Sites leveraging TheraNovex report an average 60% reduction in feasibility turnaround times alongside a 3x increase in site selection award rates for competitive global studies.

By presenting clean, verified, and accessible patient matching data, you demonstrate the highest level of operational readiness. Sponsors take note of coordinators who respect protocol design enough to validate their enrollment capabilities with hard data.

Deliver Execution Certainty with TheraNovex

Operational capability is not about working longer shifts, skipping lunch breaks to review patient charts, or making grand recruitment promises you can't keep. It is about equipping your clinical research team with the digital infrastructure needed to turn complex protocols into predictable, successful trials.

Harry Hunter

Director of Patient Recruitment Strategy

Specializing in protocol-matched patient acquisition, multi-site enrollment operations, and pre-screening workflows for clinical trials

Harry Hunter on LinkedIn